Skip to
  1. Homepage
  2. Research and trials
  3. Clinical trials
Search by disease/gene

Search by disease/gene

*
(*) mandatory field


 

Other search option(s)

75 matching term(s)

Caption : Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial

    • AUSTRALIA
    • New South Wales
    • WESTMEAD
    • A Phase II, Double Blind, Exploratory, Parallel-group, Placebo controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy - AU - (Participation is dependent on local ethics committee approval)
    • The Children's Hospital
    • Institute for Neuroscience and Muscle Research
    • More details
    • BELGIUM
    • ARRONDISSEMENT BRUSSELS-CAPITAL
    • NOT YET IDENTIFIED - BE
    • Recruiting trial
Ongoing trial
    • A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy - BE
    • NOT YET IDENTIFIED - BE
    • More details
    • BELGIUM
    • OOST-VLAANDEREN
    • GENT
    • A Phase II, Double Blind, Exploratory, Parallel-group, Placebo controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy - BE - (Participation is dependent on local ethics committee approval)
    • Ghent University Hospital - UZGent
    • NMRC - K4 - 3e verdieping
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • Phase IIa double-blind randomized placebo-controlled single-centre study to assess the efficacy and tolerability of SNT-MC17/idebenone in 8-16 year-old males with cardiac dysfunction associated with DMD - Completed-
    • University Hospitals Leuven - Gasthuisberg
    • Pediatric Neurology
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • A Phase II Open-Label Extension Study to Obtain Long-Term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001 (DELPHI Extension).
    • University Hospitals Leuven - Gasthuisberg
    • Pediatric Neurology
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
    • University Hospitals Leuven - Gasthuisberg
    • Reference Centre for NeuroMuscular Diseases - UZLeuven
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • A Phase 2b Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy.
    • University Hospitals Leuven - Gasthuisberg
    • Reference Centre for NeuroMuscular Diseases - UZLeuven
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • A phase III, randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy - BE
    • University Hospitals Leuven - Gasthuisberg
    • Reference Centre for NeuroMuscular Diseases - UZLeuven
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • Ongoing trial
    • A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystrophy - BE
    • University Hospitals Leuven - Gasthuisberg
    • Reference Centre for NeuroMuscular Diseases - UZLeuven
    • More details
    • CZECH REPUBLIC
    • Capital City Prague
    • NOT YET IDENTIFIED - CZ
    • A randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in ambulant subjects with Duchenne muscular dystrophy - CZ
    • NOT YET IDENTIFIED - CZ
    • More details
    • DENMARK
    • Jylland
    • NOT YET IDENTIFIED - DK
    • A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy - DK
    • NOT YET IDENTIFIED - DK
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Assessment of the effect of perindopril orodispersible tablet at the dose of 0.150 mg/kg/day on muscular and myocardic functions in the early stage of Duchenne Muscular Dystrophy: a two-year, double-blind, randomised, placebo-controlled study
    • CHU Paris - Hôpital Necker-Enfants Malades
    • Consultation myologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Nemucough : Evaluation of a Mechanical Insufflation-Exsufflation Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders: a Prospective, Randomized, Controlled, Multicenter Study (Phase III)
    • CHU Paris Est - Hôpital d'Enfants Armand-Trousseau
    • Service de pneumologie pédiatrique
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Recruiting trial
Ongoing trial
    • DELOS : A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients with Duchenne Muscular Dystrophy
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Myologie Centre de Recherche
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • A Phase II, Double Blind, Exploratory, Parallel-group, Placebo controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy - FR - (Participation is dependent on local ethics committee approval)
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Myologie Centre de Recherche
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Recruiting trial
Ongoing trial
    • A Phase I/II, Open-label, Dose Escalating With 48 Week Treatment Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of PRO053 in Subjects With Duchenne Muscular Dystrophy - FR
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Myologie Centre de Recherche
    • More details
    • FRANCE
    • POITOU-CHARENTES
    • POITIERS
    • Efficacy Study of Oral Glutamine Supplementation in Duchenne Muscular Dystrophy (MDB-GLN) (Phase II) - Terminated -
    • CHU de Poitiers
    • Nutrition de l'enfant
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • A randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in ambulant subjects with Duchenne muscular dystrophy - FR
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • DEMAND I: A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Subcutaneous Injections of GSK2402968 in Non-ambulant Subjects With Duchenne Muscular Dystrophy - FR
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Recruiting trial
Ongoing trial
    • A randomized, double-blind, placebo-controlled, phase III trial of Tadalafil for Duchenne Muscular Dystrophy - FR
    • NOT YET IDENTIFIED - FR
    • More details
    • GERMANY
    • Baden-Württemberg
    • FREIBURG
    • MD-NET Project R17: Immunosuppressive therapy of the Duchenne Muscular Dystrophy with low dosis Prednisone and Cyclosporin A (Phase III) - Terminated
    • Zentrum für Kinder- und Jugendmedizin Freiburg
    • Klinik für Neuropädiatrie und Muskelerkrankungen
    • More details
    • GERMANY
    • Baden-Württemberg
    • FREIBURG
    • Ongoing trial
    • DMD114044: A Phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy - DE
    • Zentrum für Kinder- und Jugendmedizin Freiburg
    • Klinik für Neuropädiatrie und Muskelerkrankungen
    • More details
    • GERMANY
    • Baden-Württemberg
    • FREIBURG
    • Ongoing trial
    • PTC124-GD-019-DMD: An open-label phase III study for previously treated Ataluren (PTC124) patients with Nonsense Mutation Dystrophinopathy - DE
    • Zentrum für Kinder- und Jugendmedizin Freiburg
    • Klinik für Neuropädiatrie und Muskelerkrankungen
    • More details
    • GERMANY
    • Baden-Württemberg
    • FREIBURG
    • Recruiting trial
Ongoing trial
    • DMD114349: An open-label phase III extension study to evaluate the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy - DE
    • Zentrum für Kinder- und Jugendmedizin Freiburg
    • Klinik für Neuropädiatrie und Muskelerkrankungen
    • More details
    • GERMANY
    • Baden-Württemberg
    • FREIBURG
    • Recruiting trial
Ongoing trial
    • PTC124-GD-020-DMD: A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy - DE
    • Zentrum für Kinder- und Jugendmedizin Freiburg
    • Klinik für Neuropädiatrie und Muskelerkrankungen
    • More details
    • GERMANY
    • Bayern
    • ERLANGEN
    • Recruiting trial
Ongoing trial
    • MD-NET Projekt P3: Preventive Treatment of left ventricular dysfunction in Duchenne Muscular Dystrophy
    • Kinder- und Jugendklinik des Universitätsklinikums Erlangen
    • Kinderkardiologische Abteilung
    • More details
    • GERMANY
    • Berlin
    • BERLIN
    • Recruiting trial
Ongoing trial
    • SUNIMUD: Multicentre, randomized, placebo controlled, double blind phase II/III study to investigate safety and tolerance of Sunphenon Epigallocatechin-Gallate (EGCg) in patients with Duchenne Muscular Dystrophy
    • Charité - Universitätsmedizin Berlin (CCM)
    • AG Klinische Neuroimmunologie
    • More details
    • GERMANY
    • Berlin
    • NOT YET IDENTIFIED - DE
    • Recruiting trial
Ongoing trial
    • FOR-DMD: Double-blind randomized phase III trial to find optimum steroid regimen for Duchenne Muscular Dystrophy - DE
    • Not yet identified - DE
    • More details
    • GERMANY
    • Berlin
    • NOT YET IDENTIFIED - DE
    • Recruiting trial
Ongoing trial
    • H6D-MC-LVJJ: A randomized, double-blind, placebo-controlled, phase III trial of Tadalafil for Duchenne Muscular Dystrophy - DE
    • Not yet identified - DE
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • ESSEN
    • PTC124-GD-007-DMD: A phase 2b efficacy and safety study of PTC124 in subjects with nonsense-mutation-mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Terminated
    • Universitätsklinikum Essen
    • Klinik für Kinderheilkunde I - Bereich Neuropädiatrie und SPZ
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • ESSEN
    • Recruiting trial
Ongoing trial
    • DELOS: A Phase III, double-blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of Idebenone in 10-18 year old patients with Duchenne Muscular Dystrophy - DE
    • Universitätsklinikum Essen
    • Klinik für Kinderheilkunde I - Bereich Neuropädiatrie und SPZ
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • ESSEN
    • Ongoing trial
    • DMD114117: A Phase II, double blind, exploratory, parallel-group, placebo controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant subjects with Duchenne Muscular Dystrophy - DE -
    • Universitätsklinikum Essen
    • Klinik für Kinderheilkunde I - Bereich Neuropädiatrie und SPZ
    • More details
    • ITALY
    • CAMPANIA
    • NAPOLI
    • Ongoing trial
    • (FOR-DMD): Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
    • AOU Seconda Università degli Studi di Napoli - Centro storico
    • Servizio di Cardiomiologia e Genetica Medica
    • More details
    • ITALY
    • LAZIO
    • ROMA
    • A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
    • IRCCS Ospedale Pediatrico Bambino Gesù
    • Unità di Malattie Neuromuscolari e Neurodegenerative, Laboratorio di Medicina Molecolare
    • More details
    • ITALY
    • LAZIO
    • ROMA
    • Ongoing trial
    • A Phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy - IT
    • IRCCS Ospedale Pediatrico Bambino Gesù
    • Unità di Malattie Neuromuscolari e Neurodegenerative, Laboratorio di Medicina Molecolare
    • More details
    • ITALY
    • LAZIO
    • ROMA
    • Recruiting trial
Ongoing trial
    • An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy (Phase III) - IT
    • IRCCS Ospedale Pediatrico Bambino Gesù
    • Unità di Malattie Neuromuscolari e Neurodegenerative, Laboratorio di Medicina Molecolare
    • More details
    • ITALY
    • LAZIO
    • ROMA
    • Recruiting trial
Ongoing trial
    • Effects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study.
    • Unione Italiana Lotta Distrofia Muscolare
    • Centro Malattie Neuromuscolari
    • More details
    • ITALY
    • LOMBARDIA
    • MILANO
    • A double-blinded randomized placebo controlled study of daily Pentoxifylline as a rescue treatment in Duchenne muscular dystrophy (CLOSED)
    • Centro Clinico Nemo
    • Unità di Neuropsichiatria Infantile
    • More details
    • ITALY
    • LOMBARDIA
    • MILANO
    • Ongoing trial
    • Cell Therapy of Duchenne Muscular Dystrophy by Intra-Arterial Delivery of HLA-Identical Allogeneic Mesoangioblasts
    • IRCCS Ospedale San Raffaele
    • Istituto di Ricerca per le Cellule Staminali
    • More details
    • ITALY
    • VENETO
    • PADOVA
    • Ongoing trial
    • (FOR-DMD): Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
    • Azienda Ospedaliera Universitaria di Padova - Campus Biomedico Pietro d'Abano
    • U.O. di Neuropatologia e Psicopatologia
    • More details
    • ITALY
    • VENETO
    • PADOVA
    • Ongoing trial
    • DELOS: A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10,18 Year Old Patients with Duchenne Muscular Dystrophy
    • Azienda Ospedaliera di Padova
    • Laboratorio di Istomorfologia e Biologia Molecolare del Rene
    • More details
    • NETHERLANDS
    • Gelderland
    • NIJMEGEN
    • Ongoing trial
    • A Phase II, Double Blind, Exploratory, Parallel-group, Placebo controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy - NL - (Participation is dependent on local ethics committee approval)
    • Radboudumc - Oost
    • Afdeling Revalidatie
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • LEIDEN
    • Exploratory study on the local dystrophin production restoring effect and safety and tolerability of a single intramuscular dose of antisense oligoribonucleotide PRO051 in Duchenne muscular dystrophy patients.
    • LUMC - Leids Universitair Medisch Centrum
    • Polikliniek Neurologie
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • LEIDEN
    • Recruiting trial
Ongoing trial
    • A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Doses of PRO044 in Patients With Duchenne Muscular Dystrophy
    • LUMC - Leids Universitair Medisch Centrum
    • Polikliniek Neurologie
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • LEIDEN
    • Ongoing trial
    • DMD114044: A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy - NL
    • LUMC - Leids Universitair Medisch Centrum
    • Polikliniek Neurologie
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • LEIDEN
    • Recruiting trial
Ongoing trial
    • An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (Phase III)
    • LUMC - Leids Universitair Medisch Centrum
    • Polikliniek Neurologie
    • More details
    • POLAND
    • Kraków
    • NOT YET IDENTIFIED - PL
    • A randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in ambulant subjects with Duchenne muscular dystrophy - PL
    • NOT YET IDENTIFIED - PL
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - ES (completed)
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • A Phase 2b Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy (terminated)
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • A Phase II, Double Blind, Exploratory, Parallel-group, Placebo controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy - ES - (Participation is dependent on local ethics committee approval) (completed)
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy - ES (completed)
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • Recruiting trial
Ongoing trial
    • An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy (Phase III) - ES
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (Phase III) - ES (terminated)
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • Recruiting trial
Ongoing trial
    • A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy - ES
    • Hospital Universitari Sant Joan de Déu
    • Servicio de neurología
    • More details
    • SPAIN
    • Comunidad Valenciana
    • VALENCIA
    • DELOS: A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients with Duchenne Muscular Dystrophy - ES (completed)
    • Hospital Universitario y Politécnico La Fe
    • Servicio de Neurología (H. La Fe)
    • More details
    • SPAIN
    • Comunidad Valenciana
    • VALENCIA
    • Recruiting trial
Ongoing trial
    • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy - ES
    • Hospital Universitario y Politécnico La Fe
    • Servicio de Neurología (H. La Fe)
    • More details
    • SPAIN
    • Comunidad Valenciana
    • VALENCIA
    • Ongoing trial
    • A Phase 3 Extension Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy - ES
    • Hospital Universitario y Politécnico La Fe
    • Servicio de Neurología (H. La Fe)
    • More details
    • SPAIN
    • Madrid
    • MADRID
    • DELOS: A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients with Duchenne Muscular Dystrophy - ES (completed)
    • Hospital Universitario 12 de Octubre
    • Sección de Neurología Infantil
    • More details
    • SWEDEN
    • Stockholms läns landsting
    • STOCKHOLM
    • A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense Mutation Mediated Duchenne and Becker Muscular Dystrophy - SE
    • Astrid Lindgren Children's Hospital - Karolinska
    • Pediatric Neurology
    • More details
    • SWEDEN
    • Västra Götalandsregionen
    • GÖTEBORG
    • Ongoing trial
    • A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystrophy - SE
    • The Queen Silvia Children's Hospital - Sahlgrenska
    • Department of Pediatrics
    • More details
    • TURKEY
    • TURKEY
    • ANKARA
    • Ongoing trial
    • A Phase II, Double Blind, Exploratory, Parallel-group, Placebo controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy - TR - (Participation is dependent on local ethics committee approval)
    • Hacettepe university
    • Pediatric Nephrology and Rheumatology Unit
    • More details
    • UNITED KINGDOM
    • Greater London
    • LONDON
    • Ongoing trial
    • Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658 (morpholino oligomer directed against exon 51)
    • Hammersmith Hospital
    • Dubowitz Neuromuscular Unit (Imperial College London)
    • More details
    • UNITED KINGDOM
    • Greater London
    • LONDON
    • Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients (phase I/II) (Completed)
    • UCL Institute of Child Health, University College London
    • Dubowitz Neuromuscular Centre
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • PTC124-GD-007e-DMD: A Phase 2b Extension Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy - UK (Prematurely Ended)
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Oxfordshire
    • OXFORD
    • Recruiting trial
Ongoing trial
    • MCRN249: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy - UK
    • John Radcliffe Hospital
    • Department of Paediatrics
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Recruiting trial
Ongoing trial
    • A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction (Phase III)
    • Freeman Hospital
    • Department of Cardiology
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Recruiting trial
Ongoing trial
    • A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of PRO053 in subjects with Duchenne muscular dystrophy - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Recruiting trial
Ongoing trial
    • A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Recruiting trial
Ongoing trial
    • A Phase III Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Ongoing trial
    • An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy (phase III) - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Recruiting trial
Ongoing trial
    • FOR-DMD: Duchenne muscular dystrophy: doubleblind randomized trial to find optimum steroid regimen (phase III) - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Ongoing trial
    • An Open-Label Study for Previously Treated Ataluren (PTC124®) Patients with Nonsense Mutation Dystrophinopathy (phase III) - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • Ongoing trial
    • PTC124-GD-007-DMD: A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy - UK
    • International Centre for Life
    • Institute of Genetic Medicine
    • More details
    • UNITED STATES
    • Florida
    • GAINESVILLE
    • Recruiting trial
Ongoing trial
    • Optical Imaging of Dystrophic and Damaged Muscle
    • UNIVERSITY OF FLORIDA
    • More details
    • UNITED STATES
    • Washington
    • NOT YET IDENTIFIED - US
    • Ongoing trial
    • PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy (Phase IV)
    • NOT YET IDENTIFIED - US
    • More details